Post-Stroke Medication Relay

Stroke, Ischemic Clinical Trial

— REMEDIPA  

Official title:

Post-Stroke Medication Relay

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04697979
• Other study ID #: 69HCL20_0713
• Status: Not yet recruiting
• Start date: February 2021
• Est. completion date: April 2022

Study information

• Verified date: January 2021
• Source: Hospices Civils de Lyon
• Contact: Xavier DODE, Dr
• Phone: 04 72 35 71 08
• Email: xavier.dode[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Prior to discharge from hospital and return home, patients managed for ischemic stroke will receive a pharmaceutical interview to discuss their discharge prescription (indication, method of administration, precautions, and possible side effects). Improvements in the use of medications in the community and in hospital follow-up. Telephone interviews or teleconsultations will make it possible to assess the patient's knowledge of his or her treatment and to re-explain it if necessary to improve patient compliance with treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: April 2022
• Est. primary completion date: February 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients managed in stroke unit following ischemic stroke
• Benefiting from a direct return home
• Non-opposition to participation

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Medication Compliance
• Stroke
• Stroke, Ischemic

Intervention

Other:
• Questionnaire
Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization. Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary.

Locations

Country	Name	City	State
France	Service de Neurologie Vasculaire, Unité 201 Hôpital Neurologique Pierre Wertheimer, HCL	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke	The value of a telephone interview / teleconsultation will be assess by comparison of treatment knowledge between the first questionnaire at one week and the second questionnaire at two months after the pharmaceutical interview and hospital discharge.; Statistical evaluation by comparative tests at one week versus two months.; Assessment will focus on treatment knowledge (score between 0 and 3), adherence (score between 0 and 6) and adverse events (score between 0 and 3)	1 week
Primary	Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke	The value of a telephone interview / teleconsultation will be assess by comparison of treatment knowledge between the first questionnaire at one week and the second questionnaire at two months after the pharmaceutical interview and hospital discharge.; Statistical evaluation by comparative tests at one week versus two months.; Assessment will focus on treatment knowledge (score between 0 and 3), adherence (score between 0 and 6) and adverse events (score between 0 and 3)	2 months